Patents

Pharmalot

Pharmalittle: Retail drug spending in the U.S. fell last year; Democrats eye patents to lower drug prices

By Ed Silverman

Pharmalot

Supreme Court to decide a patent case with big implications for small drug makers

By Ed Silverman

Pharmalot

Pharmalittle: AbbVie cancer program’s setback; Amazon hires a pharmacy expert

By Ed Silverman

German Pharma
Pharmalot

Boehringer Ingelheim abandons biosimilar sales outside the U.S.

By Ed Silverman

Pharmalot

Pharmalittle: D.C. law firms prep pharma for a Democratic house; Allergan loses another battle over Restasis patent deal

By Ed Silverman

Pharmalot

Pharmalittle: Trump hiring restrictions hurt FDA; Purdue family member has patent for addiction treatment

By Ed Silverman

Tuberculosis patient
Pharmalot

U.N. global declaration on TB passes key hurdle as U.S. and others reach a compromise

By Ed Silverman

Pharmalot

Allergan is urged to split CEO and chairman jobs by ‘disappointed’ hedge funds

By Ed Silverman

Pharmalot

Pharmalittle: Amgen migraine drug costs less than expected; J&J halts development on Alzheimer’s drug

By Ed Silverman

Pharmalot

With a push from pharma, U.S. Trade Rep pressure on Colombia starts to take hold

By Ed Silverman

Gilead Sciences
Pharmalot

Will this experimental hepatitis C treatment break Gilead’s grip on middle-income countries?

By Ed Silverman

NIH headquarters
Pharmalot

NIH is urged to probe Aegerion patents for failing to disclose federal funding

By Ed Silverman

Hepatitis C
Pharmalot

Tens of millions of people continue to lack access to hepatitis C medicines

By Ed Silverman

Gilead Sciences
Pharmalot

HHS is urged to investigate a Gilead hepatitis C patent for failing to disclose federal funding

By Ed Silverman

Anthony Anex/Keystone via AP
Pharmalot

Advocates protest Novartis ‘bullying tactics’ over access to medicines in poor countries

By Ed Silverman

Pharmalot

Pharmalittle: Will Jeff Sessions really go after opioid makers? Mylan pursues a biosimilar Botox

By Ed Silverman

Andrei Iancu - Swearing In
Pharma

The power of a patent: Will a new Trump appointee chip away at pharma’s monopolies?

By Erin Mershon

Merck logo
Pharmalot

A reversal of fortunes: Judge voids order Gilead must pay $2.5B to Merck over a patent dispute

By Ed Silverman

Pharmalot

Drug makers loathe these patent challenges, and more are being filed than ever before

By Ed Silverman

Pharmalot

Allergan may face a setback to its Mohawk deal thanks to a new ruling

By Ed Silverman

Pfizer Allergan
Pharmalot

Drug makers detest patent reviews, but what are the odds of success?

By Ed Silverman

Pharmalot

Pharmalittle: Novo blasts U.S. transparency bills; House hearing set for patents and sovereign immunity

By Ed Silverman

Pharmalot

The U.S. would pay an extra $10.7 billion without generic Allergan drug

By Ed Silverman

Capitol Building
Pharmalot

Lawmakers want probe into Allergan patent deal with Mohawk tribe

By Ed Silverman

Pharmalot

Allergan pays Mohawk tribe in a gambit to protect key patents

By Ed Silverman

Truvada bottle and pills
Pharmalot

AIDS activists urge N.Y. attorney general to probe Gilead for antitrust violations

By Ed Silverman

Pharmalot

Chilean lawmakers seek compulsory licenses for hepatitis and cancer drugs

By Ed Silverman

Eli Lilly
Pharmalot

Lilly loses a heated patent row with the Canadian government

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Trump nominee for CMS won’t say whether Medicare should negotiate drug prices

By Ed Silverman

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy